



#16 w/attach
IDS 1648
46.27.03 \$
Attorney Docket: 8321-0115 US
(formerly DIE01-NP001)

PATENT
RECEIVED
JUN 04 2003

Application of: Bernhard Dietzhold *et al.* :
Application No.: 09/816,531 : Group Art Unit: 1648
Filed: March 23, 2001 :
For: GENETICALLY ENGINEERED RABIES :
RECOMBINANT VACCINE FOR :
IMMUNIZATION OF STRAY DOGS AND :
WILDLIFE :
Examiner: L. Scheiner

INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. § 1.97(c) AND § 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty of disclosure under 37 C.F.R. §1.56, and in accordance with the practice under 37 C.F.R. §1.97(c) and §1.98, Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08A. This Information Disclosure Statement is being filed *after* receipt of the first office action but before the mailing date of a final office action under §1.113 or a Notice of Allowance under §1.311.

06/02/2003 MGBREM1 00000051 500573 09816531
01 FC:1806 180.00 CH

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)	
I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
BY	<u>Shannon R. Smith</u>
DATE:	<u>5/28/03</u>

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each, any, and all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the present applicant and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Further, Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied as prior art against the claims of the present application.

CONCLUSION

It is respectfully requested that the attached information be considered by the Examiner and that a copy of the attached Form PTO/SB/08A be returned indicating that such information has been considered.

FEE

A check is submitted herewith in satisfaction of the \$180 surcharge pursuant to 37 C.F.R. §1.17(p). The Commissioner is hereby authorized to charge any underpayment of that fee, or any other fee associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Direct Account No. 50-0573.

Respectfully submitted,
Bernard Dietzhold *et al.*

By: _____

DANIEL A. MONACO
Reg. No. 30,480
Drinker Biddle & Reath LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Tel. (215) 988-3312
Fax. (215) 988-2757
Attorney for Applicants

The PTO did not receive the following
listed item(s) a check for \$180.00

Substitute for form 1449/PTO INFORMATION DISCLOSURE CITATION IN AN APPLICATION MAY 3 0 2003 PATENT & TRADEMARK OFFICE	ATTY DOCKET NO.. 8321-0115 (37075-179015)	SERIAL NO. 09/816,513
	APPLICANT Bernard Dietzschold et al.	
	FILING DATE March 23, 2001	GROUP 1648

U.S. PATENT DOCUMENTS

EXR. INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
AA	5,853,735	12/29/1998	Benejean et al.	424	208.1	

FOREIGN PATENT DOCUMENTS


	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA TION YES	NO
AB	WO 01/70932	9/27/01	WO	C12N			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Allen and Seed (1989) <i>Science</i> 243:378-80
AD	Berg et al. (1995) <i>J. Clin. Invest.</i> 96:2339-2347
AE	Bogdan et al. (1991) <i>J. Exp. Med.</i> 174:1549-1555
AF	Carrera et al. (1996) <i>J. Exp. Med.</i> 183:515-526
AG	Cassatella et al. (1989) <i>J. Exp. Med.</i> 169:549-567
AH	Chattergoon et al. (2000) <i>Nat. Biotech.</i> 18: 974-979
AI	Chehimi et al. (1994) <i>J. Exp. Med.</i> 179:1361-1366
AJ	Cohn et al. (1946) <i>J. Am. Chem. Soc.</i> 68:459-475
AK	Conzelman (1998) <i>Ann. Rev. Genet.</i> 32: 123-162
AL	Dalrymple et al. (1995) <i>Infect. Immun.</i> 63:2262-2268
AM	D'Andrea et al. (1993) <i>J. Exp. Med.</i> 178:1041-1048
AN	Davidson et al. (1996) <i>J. Exp. Med.</i> 184:241-251
AO	Dietzschold et al. (1983) <i>Proc. Natl. Acad. Sci. USA</i> 80:70-74
AP	Dietzschold et al. (1985) <i>J. Virol.</i> 56: 12-18
AQ	Dietzschold et al. (1999) <i>Molecular Pathogenesis of Rabies</i> , Abstract Presentation, 10 th Annual Rabies in Americas, Nov. 14-19, San Diego, CA
AR	Dietzschold et al. (2000) <i>J. Human Virol.</i> 3:50-57
AS	Faber et al. (2002) <i>J. Virol.</i> 76: 3374-3381
AT	Finke et al. (2000) <i>J. Virol.</i> 74: 7261-7269

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Sheet 2 of 3


Substitute for form 1449/PTO INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	ATTY DOCKET NO.. 8321-0115 (37075-179015)	SERIAL NO.. 09/816,513
	APPLICANT Bernard Dietzschold et al.	
	FILING DATE March 23, 2001	GROUP 1648

JUN 04 2003

TECH CENTER 1600/2900

AU	Fiorentino et al. (1991) <i>J. Immunol.</i> 146:3444-3451
AV	Galelli et al. (2000) <i>J. Neurovirol.</i> 6: 359-372
AW	Gavin et al. (1998) <i>J. Immunol.</i> 160:20-23
AX	Germann et al. (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:4823-4827
AY	Hale et al. (1988) <i>Lancet</i> 2:1394-1399
AZ	Hart et al. (1995) <i>Immunol.</i> 84:536-542
BA	Hazenbos et al. (1996) <i>Immunity</i> 5:181-188
BB	Heinzel et al. (1993) <i>J. Exp. Med.</i> 177:1505-1512
BC	Howard et al. (1993) <i>J. Exp. Med.</i> 177:1205-1208
BD	Jallet et al. (1999) <i>J. Virol.</i> 73: 225-233
BE	Jones et al. (1986) <i>Nature</i> 321:522-525
BF	Karp et al. (1996) <i>Science</i> 273:228-231
BG	Kincy-Cain et al. (1996) <i>Infect. Immun.</i> 64:1437-1440
BH	Kleinveld et al. (1988) <i>Scand. J. Rheumatology</i> 75:157-163
BI	Kothakota et al. (1997) <i>Science</i> 278: 294-297
BJ	Kunkel et al. (1988) <i>J. Biol. Chem.</i> 263:5380-5384
BK	Lee et al. (1988) <i>J. Chromatography</i> 444:141-52
BL	Leonard et al. (1995) <i>J. Exp. Med.</i> 181:381-386
BM	Malefyt et al. (1991) <i>J. Exp. Med.</i> 174:1209-1220
BN	Malefyt et al. (1991) <i>J. Exp. Med.</i> 174:915-924
BO	Mattner et al. (1996) <i>Eur. J. Immunol.</i> 26:1553-1559
BP	Mebatsion et al. (1995) <i>J. Virol.</i> 69(3):1444-1451
BQ	Mebatsion et al. (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93(21):11366-11370
BR	Morimoto et al. (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:5653-5658
BS	Morimoto et al. (1999) <i>J. Virol.</i> 73: 510-517
BT	Morimoto et al. (2000) <i>J. Neurovirol.</i> 6: 373-381
BU	Morimoto et al. (2001) <i>Vaccine</i> 19:3543-3551
BV	Muta et al. (1994) <i>Nature</i> 368:70-73
BW	Nathan (1987) <i>J. Clin. Invest.</i> 79:319-326

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Substitute for form 1449/PTO INFORMATION DISCLOSURE CITATION IN AN APPLICATION 	ATTY DOCKET NO.. 8321-0115 (37075-179015)	SERIAL NO.. 09/816,481 RECEIVED JUN 04 2003
	APPLICANT Bernard Dietzschold et al.	
	FILING DATE March 23, 2001	GROUP 1648 TECH CENTER 1600/2900

BX	Noel et al. (1992) <i>J. Infec. Dis.</i> 166:178-182
BY	Oncley et al. (1949) <i>J. Am. Chem. Soc.</i> 71:541-550
BZ	Pulmanausahakul et al. (2001) <i>J. Virol.</i> 75(22): 10800-10807
CA	Queen et al. (1989) <i>Proc. Natl. Acad. Sci. USA</i> 86:10029-10033
CB	Reid et al. (1997) <i>J. Immunol.</i> 159:970-975
CC	Reiner et al. (1993) <i>J. Immunol. Methods</i> 165:37-46
CD	Restifo (2000) <i>Curr. Opin. Immunol.</i> 12: 597-603
CE	Rovere et al. (1998) <i>J. Immunol.</i> 161: 4467-4471
CF	Sasaki et al. (2001) <i>Nat. Biotech.</i> 19: 543-547
CG	Schnell et al. (1999) <i>Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1</i> , Abstract Presentation, 10 th Annual Rabies in the Americas, Nov. 14-19, San Diego, CA
CH	Sears et al. (1990) <i>J. Immunol.</i> 144:371-78
CI	Shi et al. (2000) <i>Proc. Natl. Acad. Sci. USA</i> 97: 14590-14595
CJ	Sutterwala et al. (1997) <i>J. Exp. Med.</i> 185:1977-1985
CK	Sutterwala et al. (1996) <i>J. Leukocyte Biol.</i> 59:883-890
CL	Takai et al. (1994) <i>Cell</i> 76:519-529
CM	Takai et al. (1996) <i>Nature</i> 379:346-349
CN	Tankersley (1994) <i>Immunol. Reviews</i> 139:159-172
CO	Trembleau et al. (1995) <i>J. Exp. Med.</i> 181:817-821.
CP	Trinchieri et al. (1996) <i>J. Leukocyte Biol.</i> 59:505-511
CQ	Tripp et al. (1993) <i>Proc. Natl. Acad. Sci. USA</i> 90:3725-3729
CR	Tsunawaki et al. (1988) <i>Nature</i> 334:260-262
CS	Verhoeven et al. (1988) <i>Science</i> 239:1534-1536
CT	Vialtel et al. (1982) <i>J. Biol. Chem.</i> 257:3811-3818
CU	Virag et al. (1998) <i>Immunol.</i> 94: 345-355
CV	Wiktor (1977) <i>Proc. Natl. Acad. Sci. USA</i> 74: 334-338
CW	Wright et al. (1980) <i>Biochem J.</i> 187:767-774
CX	Wysocka et al. (1995) <i>Eur. J. Immunol.</i> 25:672-676
CY	Yan et al. (2001) <i>J. Neurovirol.</i> 7: 518-527

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	